Download PDF
Horm Metab Res 2008; 40(4): 245-250
DOI: 10.1055/s-2008-1046798
Original Basic

© Georg Thieme Verlag KG Stuttgart · New York

Levonorgestrel Antagonism on Estrogen-induced Pituitary Tumors Is Mediated by Progesterone Receptors

E. B. Rey-Roldán 1 , C. A. Grillo 2 , 3 , L. Pietranera 2 , 3 , C. Libertun 1 , 4 , A. F. De Nicola 2 , 3 , G. G. Piroli 2 , 3
  • 1Laboratory of Neuroendocrinology, Instituto de Biología y Medicina Experimental, CONICET, Vuelta de Obligado 2490, Buenos Aires, Argentina
  • 2Laboratory of Neuroendocrine Biochemistry, Instituto de Biología y Medicina Experimental, CONICET, Vuelta de Obligado 2490, Buenos Aires, Argentina
  • 3Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Buenos Aires, Argentina
  • 4Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Buenos Aires, Argentina
Further Information

Publication History

received 07.05.2007

accepted 20.09.2007

Publication Date:
05 March 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Using both in vitro and in vivo approaches, we studied the antagonism exerted by the synthetic progestin levonorgestrel on estrogen-induced prolactinomas, considering that levonorgestrel shows partial androgenic properties and that androgens inhibit estrogen-induced prolactin synthesis and secretion. In the tumors, binding of estrogens to their receptors was competed neither by progesterone receptor ligands nor by androgen receptor ligands, ruling out direct inhibitory effects of these drugs on tumor development. Progestin binding was competed by the progesterone receptor agonists progesterone and levonorgestrel, by the antagonist mifepristone, and also by the androgen dihydrotestosterone, whereas the androgen receptor antagonist hydroxyflutamide was a weak competitor. In addition, both progesterone receptor and androgen receptor ligands competed for binding to androgen receptors. In primary cultures of pituitary tumors, levonorgestrel decreased prolactin secretion, an effect that was blocked by mifepristone but not by hydroxyflutamide. In vivo results indicated that levonorgestrel inhibition of both estrogen-induced pituitary weight increment and hyperprolactinemia was reduced by mifepristone, whereas flutamide was unable to block levonorgestrel effects. Our results suggest that even when an interaction of levonorgestrel with androgen receptors in the tumors is possible, the antagonistic effects of levonorgestrel on tumor development and functionality are mediated by progesterone receptors.

Key words

prolactin - mifepristone - RU486 - flutamide - progestin

References

  • 1 Wiklund J, Wertz N, Gorski JA. A comparison of estrogen effects on uterine and pituitary growth and prolactin synthesis in F344 and Holtzman rats.  Endocrinology. 1981;  109 1700-1707
    PubMedGoogle Scholar
  • 2 Piroli GG, Grillo CA, Ferrini MG, Lux-Lantos V, De Nicola AF. Antagonism by progesterone of diethylstilbestrol-induced pituitary tumorigenesis in Fischer 344 rats: effects on sex steroid receptors and tyrosine hydroxylase mRNA.  Neuroendocrinology. 1996;  63 530-539
    PubMedGoogle Scholar
  • 3 Piroli GG, Torres A, Grillo CA, Lux-Lantos V, Aoki A, De Nicola AF. Mechanisms in progestin antagonism of pituitary tumorigenesis.  J Steroid Biochem Molec Biol. 1998;  64 59-67
    PubMedGoogle Scholar
  • 4 Piroli GG, Cassataro J, Pietranera L, Grillo CA, Ferrini M, Lux-Lantos V, De Nicola AF. Progestin regulation of galanin and prolactin gene expression in oestrogen-induced pituitary tumours.  J Neuroendocrinol. 2001;  13 302-309
    CrossrefPubMedGoogle Scholar
  • 5 Spona J. Androgenic action of progestins and possible synandrogenic properties of antiandrogens used in oral contraceptives.  Gynecol Obstet Invest. 1984;  17 66-72
    PubMedGoogle Scholar
  • 6 Phillips A, Demarest K, Hahn DW, Wong F, MacGuire JL. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.  Contraception. 1990;  41 399-410
    CrossrefPubMedGoogle Scholar
  • 7 Kuhnz W, Beier S. Comparative progestational and androgenic activity of norgestimate and levonorgestrel in the rat.  Contraception. 1994;  49 275-289
    CrossrefPubMedGoogle Scholar
  • 8 Cabeza M, Vilchis F, Lemus AE, Díaz de León L, Pérez-Palacios G. Molecular interactions of Levonorgestrel and its 5α-reduced derivative with androgen receptors in hamster flanking organs.  Steroids. 1995;  60 630-635
    CrossrefPubMedGoogle Scholar
  • 9 Morali G, Lemus AE, Munguía R, García GA, Grillasca I, Pérez-Palacios G. Hormone-like behavioral effects of levonorgestrel and its metabolites in the male rat.  Pharmacol Biochem Behav. 2002;  73 951-961
    CrossrefPubMedGoogle Scholar
  • 10 Giguère V, Meunier H, Veilleux R, Labrie F. Direct effects of sex steroids on prolactin release at the anterior pituitary level: Interactions with dopamine, thyrotropin-releasing hormone, and isobutylmethylxanthine.  Endocrinology. 1982;  111 857-862
    PubMedGoogle Scholar
  • 11 Tong Y, Simard J, Labrie C, Zhao HF, Labrie F, Pelletier G. Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland.  Endocrinology. 1989;  125 1821-1828
    PubMedGoogle Scholar
  • 12 Thieulant M-L, Duval J. Differential distribution of androgen and estrogen receptors in rat pituitary cell populations separated by centrifugal elutriation.  Endocrinology. 1985;  116 1299-1303
    PubMedGoogle Scholar
  • 13 Weisenberg LS, Piroli GG, Heller CL, De Nicola AF. Binding of steroids in nuclear extracts and cytosol of rat pituitary and estrogen-induced pituitary tumors.  J Steroid Biochem. 1987;  28 683-689
    CrossrefPubMedGoogle Scholar
  • 14 Rey-Roldán EB, Lux-Lantos AR, González-Iglesias AE, Becú-Villalobos D, Libertun C. Baclofen, a gamma-aminobutyric acid B agonist, modifies hormonal secretion in pituitary cells from infantile female rats.  Life Sci. 1996;  58 1059-1065
    CrossrefPubMedGoogle Scholar
  • 15 González Iglesias A, Díaz-Torga G, Piroli GG, Achával-Zaia R, De Nicola AF, Libertun C, Becú-Villalobos D. Bromocriptine restores angiotensin II response in pituitary hyperplasia.  Mol Cell Endocrinol. 2000;  165 67-74
    CrossrefPubMedGoogle Scholar
  • 16 Sourla A, Richard V, Labrie F, Labrie C. Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin.  J Endocrinol. 2000;  166 455-462
    CrossrefPubMedGoogle Scholar
  • 17 Jellinck PH, Newcombe A-M. Androgen receptor-mediated inhibition of estrogen-induced uterine peroxidase.  J Steroid Biochem Mol Biol. 1983;  19 1713-1717
    PubMedGoogle Scholar
  • 18 Jellinck PH, Newcombe A-M, Lyttle CR. Antiandrogenic property of RU 486: Enhancement of estrogen-induced uterine peroxidase activity in the rat.  J Steroid Biochem Mol Biol. 1993;  45 303-307
    CrossrefPubMedGoogle Scholar
  • 19 Song L-N, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.  Mol Endocrinol. 2004;  18 70-85
    PubMedGoogle Scholar
  • 20 Lemus AE, Vilchis F, Damsky R, Chávez BA, García GA, Grillasca I, Pérez-Palacios G. Mechanism of action of levonorgestrel: in vivo metabolism and specific interactions with steroid receptors in target organs.  J Steroid Biochem Mol Biol. 1992;  41 881-890
    CrossrefPubMedGoogle Scholar
  • 21 Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines.  J Steroid Biochem Mol Biol. 1995;  55 423-437
    CrossrefPubMedGoogle Scholar
  • 22 Szabo M, Kilen SM, Saberi S, Ringstrom SJ, Schwartz NB. Antiprogestins suppress basal and activin-stimulated follicle-stimulating hormone secretion in an estrogen-dependent manner.  Endocrinology. 1998;  139 2223-2228
    CrossrefPubMedGoogle Scholar
  • 23 Bellido C, González D, Aguilar R, Sánchez-Criado JE. Antiprogestins RU486 and ZK299 suppress basal and LHRH-stimulated FSH and LH secretion at pituitary level in the rat in an oestrous cycle stage-dependent manner.  J Endocrinol. 1999;  163 79-85
    CrossrefPubMedGoogle Scholar
  • 24 Hackenberg R, Hawighorst T, Filmer A, Nia AH, Schulz KD. Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor.  Breast Cancer Res Treat. 1993;  25 217-224
    CrossrefPubMedGoogle Scholar
  • 25 Brann DW, Putnam CD, Mahesh BV. Similarities and differences in progesterone and androgens in modulation of LH, FSH and PRL release: unexpected properties of flutamide.  J Steroid Biochem. 1990;  36 287-294
    CrossrefPubMedGoogle Scholar
  • 26 Sambaziotis D, Kapranos N, Kontogeorgos G. Correlation of Bcl-2 and Bax with apoptosis in human pituitary adenomas.  Pituitary. 2003;  6 127-133
    CrossrefPubMedGoogle Scholar
  • 27 Farrell WE. Epigenetic mechanisms of tumorigenesis.  Horm Metab Res. 2005;  37 361-368
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Lamberts SW, Verleun T, Hofland L, Oosterom R. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells.  J Clin Endocrinol Metab. 1986;  63 1342-1347
    PubMedGoogle Scholar
  • 29 Rey-Roldán EB, Bianchi MS, Bettler B, Becú-Villalobos D, Lux-Lantos VA, Libertun C. Adenohypophyseal and hypothalamic GABA B receptor subunits are downregulated by estradiol in adult female rats.  Life Sci. 2006;  79 342-350
    CrossrefPubMedGoogle Scholar
  • 30 Piroli GG, Grillo CA, Ferrini MG, Díaz-Torga G, Rey EB, Libertun C, De Nicola AF. Restoration by bromocriptine of glucocorticoid receptors and glucocorticoid negative feedback on prolactin secretion in estrogen-induced pituitary tumors.  Neuroendocrinology. 1993;  58 273-279
    PubMedGoogle Scholar
  • 31 Yonezawa K, Tamaki N, Kokunai T. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.  Neurol Med Chir (Tokyo). 1997;  37 901-906
    PubMedGoogle Scholar
  • 32 Gruszka A, Kunert-Radek J, Pawlikowski M. The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma.  Folia Histochem Cytobiol. 2004;  42 35-39
    PubMedGoogle Scholar
  • 33 Molitch ME. Pharmacologic resistance in prolactinoma patients.  Pituitary. 2005;  8 43-52
    CrossrefPubMedGoogle Scholar
  • 34 Daly AF, Jaffrain-Rea M-L, Beckers A. Clinical and genetic features of familial pituitary adenomas.  Horm Metab Res. 2005;  37 347-354
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 World Health Organization .Medical Eligibility Criteria for Contraceptive Use. Geneva 2004 third ed
  • 36 Ironside W, Dangerfield VJM, Timperley WR, Underwood JCE. Steroid hormone receptors in pituitary adenomas: A biochemical, immunohistochemical and morphometric study on cryostat sections.  Neuropathol Appl Neurobiol. 1986;  12 539-546
    PubMedGoogle Scholar
  • 37 Caronti B, Palladini G, Bevilacqua M-G, Petrangeli E, Fraioli B, Cantore G, Tamburrano G, Carapella CM, Jaffrain-Rea M-L. Effects of 17β-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: Correlation with specific cellular receptors.  Tumor Biol. 1993;  14 59-68
    PubMedGoogle Scholar
  • 38 Caronti B, Palladini G, Calderaro C, Bevilacqua M-G, Petrangeli E, Esposito V, Tamburrano G, Gulino A, Jaffrain-Rea M-L. Effects of gonadal steroids on the growth of human pituitary adenomas in vitro.  Tumor Biol. 1995;  16 353-364
    PubMedGoogle Scholar
  • 39 Jaffrain-Rea ML, Petrangeli E, Ortolani F, Fraioli B, Lise A, Esposito V, Spagnoli LG, Tamburrano G, Frati L, Gulino A. Cellular receptors for sex steroids in human pituitary adenomas.  J Endocrinol. 1996;  151 175-184
    CrossrefPubMedGoogle Scholar
  • 40 Hamilton DK, Vance ML, Boulos PT, Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.  Pituitary. 2005;  8 53-60
    CrossrefPubMedGoogle Scholar

Correspondence

G.G. Piroli

Department of Pharmacology

Physiology, and Neuroscience

University of South Carolina School of Medicine

6439 Garners Ferry Rd, Bldg 1, Rm D4

Columbia

South Carolina 29209

USA

Phone: +1/803/733 32 19

Fax: +1/803/733 15 23

Email: gpiroli@gw.med.sc.edu